secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVAI BIO, INC. (AVAI)
CIK:        0001740797
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001740797-25-000047
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avant Technologies enters joint venture with Austrianova to form Klothonova for Klotho-based therapies
--------------------------------------------------------------------------------

- AVAI and Austrianova form Klothonova Inc., a 50/50 joint venture to develop treatments for Alzheimer's, heart disease, cancer, kidney disease, and longevity.
- AVAI will fund Klothonova's operations for 18 months up to $1.5M in exchange for 1.5M shares (50% ownership).
- Austrianova contributes its proprietary cell encapsulation technology and IP as an exclusive license to Klothonova.
- Potential additional $8.5M loan from AVAI for clinical development; if AVAI declines, Austrianova can pursue development outside Klothonova.
- Kenn Kerr named CEO; Walter H. Günzburg, Ph.D., appointed Chairman of the Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000047/0001740797-25-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740797/000174079725000047/form8_avai.htm
  HTML page:      https://secwatch.observer/filing/0001740797-25-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer